Valeant Pharmaceuticals entered into a licensing agreement with Norgine for a bowel-cleansing oral solution used to prepare for colonoscopies.
EndoChoice reported total revenue for the second quarter of 2016 was $19.3 million, but net loss for the second quarter totaled $24.7 million.
EndoChoice’s Lumos received FDA clearance and was recently launched in the United States.
More articles on GI/endoscopy:
5 most read GI/endoscopy stories: Aug. 1 — Aug. 5
EndoChoice launches the Lumos imaging software system: 4 takeaways
Dr. Farzana Rashid Hossain appointed to 1st Philadelphia Commission for Women — 4 thoughts
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
